We created the infographic below using World Health Organization data.  The anticipated rise in global Cardiovascular Disease deaths is staggering – especially when you realize it is already the leading cause of death globally.  Cardiovascular disease is a global issue that is significantly impacting the western world as well as developing countries.

For drug developers, these emerging markets provide access to large patient populations and the potential of accelerated clinical trial patient enrollments.  However, other factors such as regulatory environments regarding ICH-GCP standards and the availability of expert CV investigators need to be fully examined before site selection and patient enrollment begin.

Clinipace experts recently shared their knowledge of effective site selection for CV trials in a comprehensive whitepaper entitled Trends and Considerations on Global Cardiovascular Drug Development.